licensing

News

When licensing deals go bad - Novo sues KBP Bio for $830m

Novo Nordisk lawsuit claims KBP concealed clinical data ahead of a $1.3bn licensing deal for blood pressure drug candidate ocedurenone.

News

Roche licenses Innovent ADC that could challenge Amgen drug

Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.

News

MSD makes its obesity move with $2bn Hansoh deal

MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.

News

GSK builds neuro, cancer pipeline with trio of deals

GSK has added to its R&D pipeline via partnerships with Muna Therapeutics, Rgenta Therapeutics, and Duality Biologics.

News

Genmab expands its pipeline with $630m Scancell deal

Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.

News

Gilead looks beyond Trodelvy with Tubulis alliance

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.

When licensing deals go bad - Novo sues KBP Bio for $830m

Roche licenses Innovent ADC that could challenge Amgen drug

MSD makes its obesity move with $2bn Hansoh deal

GSK builds neuro, cancer pipeline with trio of deals

Genmab expands its pipeline with $630m Scancell deal

Gilead looks beyond Trodelvy with Tubulis alliance

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

licensing

Editor's Picks